CYDY News and Press, CytoDyn Inc From 01/10/22

Regnum Signs Assignment and Assumption Agreement with CytoDyn and SevenScore Pharmaceuticals to Commercialize Leronlimab in the U.S. for the Treatment of HIV In exchange for the exclusive right to market and distribute leronlimab in the U.S. for HIV-related indications, SevenSco...

CytoDyn previously hit a primary endpoint in a pivotal Phase 3 HIV trial with some HTE patients; over 20 patients remain in an extension arm study for up to 4 years CytoDyn will include some findings from this study in its BLA submission for HIV approval CytoDyn Inc....

Primary endpoint (PDFF) was achieved in both Intention to Treat and Per Protocol Populations CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic i...

Gilead's businesses have numerous struggles, especially its core HIV businesses, which can cost it billions. The company is focused on pivoting away from HIV and toward a growing oncology business, having spent $10s of billions to do so. The company will definitely grow revenue, b...

Court order requires CRO to provide CytoDyn full access to all its clinical trial data CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for mult...

CytoDyn (OTCQB:CYDY) has received a positive response from the FDA to conduct a Phase 3, placebo controlled trial to evaluate the efficacy and safety of leronlimab in combination with standard of care for critically ill patients with COVID-19 pneumonia with need for Invasive Mechanical Ventil...

FDA also allows integrated or meta-analysis of the previous trial results in CD20 final analysis CD20 is allowed to have four dosages of leronlimab in the first four weeks via IV infusion CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company ...

Leronlimab is a unique molecule targeting a unique pathway, which gives it strength in numerous indications. The company's press doesn't correlate with its value according to the market or other pharmaceutical companies. The company's annoying ability of refusing to admit mistakes...

Average cT1 Reduction of 31.2 msec Over 14 Weeks for all 20 Patients More than 80% of patients (5 out of 6) with severe NASH (cT1>1000 msec) had an average cT1 drop of 108 msec (-48 to -238 msec) and an average of about 20% fatty deposit reduction 11 of 20 patients ...

VANCOUVER, Washington, Dec. 10, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today Nader Pourhassan, Ph.D.,...